TipRanks

Notifications

India Globalization Capital announces rebranding to IGC Pharma

India Globalization Capital will begin operating under the new name IGC Pharma, effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future. Common stock will continue to be quoted on the NYSE American under the same symbol IGC. Trading of common stock under the new name will commence on March 31, 2023. CUSIP and EIN numbers will remain the same.The name change to IGC Pharma, Inc. acknowledges the Company’s identity as a developer of drug assets for treating diseases, including, but not limited to, Alzheimer’s disease. IGC believes it has the first natural, cannabis-based, patent-protected compound that relies on low doses of THC, a psychoactive cannabinoid, and another compound as pharmaceutically active agents for the treatment of Alzheimer’s disease. IGC is currently in a Phase 2 trial with its THC-based investigational medication, IGC-AD1, for the treatment of agitation in Alzheimer’s. IGC-AD1 is the only natural, THC-based investigational drug candidate currently undergoing FDA trials on Alzheimer’s. The APIs in IGC Pharma’s leading drug asset, IGC-AD1, have shown in preclinical studies on Alzheimer’s cell lines the potential to be effective in ameliorating a key protein responsible for Abeta plaques, a key hallmark of Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome, menstrual cramps and sleep disorders.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IGC:

Tags: ,